Quick Facts
  • pin location icon
    Primary Location:
    Cleveland Clinic Cancer Center
  • wavy circle icon with check mark inside
    Thoracic Malignancies
    Clinical Research
  • magnifying glass with heart icon
  • gender symbols interlocked icon
  • chat box with different language translations icon
  • certificate with a ribbon icon below
    Med School:
    University of Florida College of Medicine

Get to Know Dr. Nathan Pennell 

Dr. Nathan Pennell is a medical oncologist at the Taussig Cancer Institute at the Cleveland Clinic. He focuses on thoracic malignancies, with a particular interest in mesothelioma, and was appointed director of the lung cancer medical oncology program in 2010. He is a professor of medicine at the Cleveland Clinic Lerner College of Medicine.

Pennell achieved a Ph.D. in neuroscience in 1998, and graduated from the University of Florida School of Medicine in 2002. He has been at the Cleveland Clinic since 2008, with research interests that include mesothelioma treatment and clinical trials using novel therapies.

He completed his internship and residency in Boston at Brigham and Women’s Hospital in 2005 and finished his fellowship in 2007 at the nearby Dana-Farber Cancer Institute.

Pennell completed additional training at the Harvard T.H. Chan School of Public Health in the clinical effectiveness program.

Contact Dr. Nathan Pennell
Mesothelioma specialist speaking with a patient and his wife
Talk to a Doctor About Your Diagnosis
We can help you or a loved one get in contact with Dr. Pennell and find the treatment that’s best for you.

Specialties of Dr. Nathan Pennell

  • Pleural and lung cancer
  • Research

Dr. Nathan Pennell’s Experience and Medical Education

  • Taussig Cancer Institute
  • University of Florida College of Medicine (M.D.)
  • Brigham and Women’s Hospital (Residency)
  • Dana-Farber Cancer Institute (Fellowship)

Awards and Certifications

  • Board certified in medical oncology
  • Board certified in internal medicine

Publications of Dr. Nathan Pennell

  • Drilon, A. et al. (2020, August 27). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer. New England Journal of Medicine.
  • Rivera, D.R. et al. (2020, July 22). Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discovery.
  • Zagouras, A. et al. (2020, June 21). Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade Induced Diabetes. Oncologist.
  • Kuderer, N.M. et al. (2020, June 20). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet.
  • Choi, H. & Pennell, N.A. (2020, May). Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening. Oncologist.